Choline to N-Acetylaspartate Ratio in Glioblastoma Recurrence Diagnosis

1H-MRS parameters in non-enhancing peritumoral regions can predict the recurrence of glioblastoma
Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI
The Brain Imaging Collaboration Suite (BrICS): A Cloud Platform for Integrating Whole-Brain Spectroscopic MRI into the Radiation Therapy Planning Workflow
Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging
Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping
Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy
Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme

The Choline to N-Acetylaspartate Ratio is one of the most studied metabolic markers in glioblastoma (GBM) using proton magnetic resonance spectroscopy (1H-MRS). It is particularly valuable in assessing tumor activity and glioblastoma recurrence diagnosis due to its sensitivity to changes in cellular metabolism and neuronal integrity.

Biological Basis

- Choline (Cho): Reflects cell membrane turnover and proliferation. Elevated levels are associated with active tumor growth, as glioblastoma cells have high membrane turnover.

- N-Acetylaspartate (NAA): A marker of neuronal health and density, primarily present in normal brain tissue. Its levels decrease in areas infiltrated or destroyed by glioblastoma.

As glioblastoma recurs, tumor metabolism and infiltration lead to:

- Increased Cho due to tumor cell proliferation.

- Decreased NAA due to destruction of normal neuronal tissue.

This results in a higher Cho/NAA ratio, making it a reliable marker for distinguishing recurrent glioblastoma from non-tumor-related changes, such as radiation necrosis or post-treatment effects.

—

### Clinical Utility

1. Diagnosis of Recurrence:

A significantly elevated Cho/NAA ratio is indicative of tumor recurrence in previously treated glioblastoma patients.
Differentiates recurrent tumor tissue from non-tumorous post-therapeutic changes, which typically do not exhibit high Cho levels.

2. Threshold Values:

Research indicates that Cho/NAA > 1.99 is associated with a high risk of recurrence.
This threshold can stratify patients into low-risk and high-risk categories for glioblastoma recurrence.

3. Spatial Mapping of Recurrence:

Multivoxel 1H-MRS allows mapping of metabolic activity across non-enhancing peritumoral regions (NEPTRs).
Higher Cho/NAA ratios in NEPTRs identify regions prone to early recurrence.

—

### Advantages - Non-Invasive: Allows metabolic assessment without requiring a biopsy. - Predictive Value: Detects recurrence earlier than structural changes visible on conventional MRI. - Guidance for Treatment: Identifies high-risk regions for targeted interventions, such as radiotherapy or re-resection.

—

### Limitations 1. Overlap with Radiation Necrosis:

While Cho/NAA is elevated in recurrent tumors, some overlap can occur with radiation necrosis, requiring additional markers or imaging techniques for confirmation.

2. Variability in Thresholds:

Threshold values (e.g., Cho/NAA > 1.99) may vary across studies due to differences in MRS acquisition parameters and MRI field strengths.

3. Spatial Resolution:

The resolution of multivoxel 1H-MRS may not detect very small infiltrative lesions, potentially underestimating recurrence.

4. Technical Requirements:

Requires advanced imaging protocols, robust co-registration with anatomical MRI, and expertise in interpretation.

Future Directions

Integration with Molecular Markers:

Combining Cho/NAA ratios with genomic markers (e.g., IDH mutation, MGMT methylation) could enhance diagnostic accuracy.

Longitudinal Monitoring:

Repeated Cho/NAA measurements over time may offer insights into tumor progression or response to therapy.

- Artificial Intelligence:

Machine learning models trained on metabolic data could improve the prediction of recurrence and automate analysis.

Conclusion

The Cho/NAA ratio is a powerful metabolic biomarker for diagnosing glioblastoma recurrence, particularly in challenging cases where traditional imaging is inconclusive. Its ability to highlight areas of active tumor metabolism provides critical insights for early detection and personalized management, though further validation and standardization are necessary for widespread clinical adoption.

A study of Lu et al. aimed to evaluate the predictive value of metabolic parameters in preoperative non-enhancing peritumoral regions (NEPTRs) for glioblastoma recurrence diagnosis, using multivoxel hydrogen proton magnetic resonance spectroscopy (1H-MRS). Clinical and imaging data from patients with recurrent glioblastoma were analyzed. Through co-registration of preoperative and post-recurrence MRI, they identified future tumor recurrence regions (FTRRs) and future non-tumor recurrence regions (FNTRRs) within the NEPTRs. Metabolic parameters were recorded separately for each region. Cox regression analysis was applied to assess the association between metabolic parameters and glioblastoma recurrence. Compared to FNTRRs, FTRRs exhibited a higher Cho/Cr ratio, higher Cho/NAA ratio, and lower NAA/Cr ratio. Both Cho/NAA and Cho/Cr ratios were recognized as risk factors in univariate and multivariate analyses (P < 0.05). The Cox regression model indicated that Cho/NAA > 1.99 and Cho/Cr > 1.73 are independent risk factors for early glioblastoma recurrence. Based on these cut-off values, patients were stratified into low-risk and high-risk groups, with a statistically significant difference in recurrence rates between the two groups (P < 0.01). The Cho/NAA and Cho/Cr ratios in NEPTRs are independent predictors of future glioblastoma recurrence. Specifically, Cho/NAA > 1.99 and/or Cho/Cr > 1.73 in NEPTRs may indicate a higher risk of early postoperative recurrence at these regions ¹⁾.

This study demonstrates that metabolic ratios (Cho/NAA and Cho/Cr) in NEPTRs are independent predictors of glioblastoma recurrence and proposes clinically relevant cut-off values for risk stratification. While the findings are promising, limitations such as small sample size, lack of external validation, and potential confounding factors highlight the need for further research. The integration of metabolic and molecular data, along with validation in larger cohorts, could significantly enhance the clinical utility of these predictors.

¹⁾

Lu W, Feng J, Zou Y, Liu Y, Gao P, Zhao Y, Wu X, Ma H. 1H-MRS parameters in non-enhancing peritumoral regions can predict the recurrence of glioblastoma. Sci Rep. 2024 Nov 26;14(1):29258. doi: 10.1038/s41598-024-80610-z. PMID: 39587278.